VMET Market Analysis
Fundamentals
Updated daily after market closeValuation
- Forward P/E
- 32.47
- PEG ratio
- —
- P/B
- 2.62
- P/S (TTM)
- 17.35
- EV/EBITDA
- 14.13
Profitability & growth
- ROE (TTM)
- 11.2%
- Operating margin
- 90.6%
- Revenue growth YoY
- 594.0%
- Dividend yield
- —
- Beta
- —
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Versamet Royalties Corporation Common Stock
Company profileViamet Pharmaceuticals Corp (VMET) is an innovative biopharmaceutical company dedicated to the development of advanced therapeutics targeting serious diseases, particularly in the areas of fungal infections and oncology, utilizing its proprietary metalloenzyme-based technology platform. With a robust and diversified clinical pipeline supported by strategic partnerships and a comprehensive intellectual property portfolio, Viamet is strategically positioned for significant growth. The company remains focused on addressing critical unmet medical needs and is committed to enhancing shareholder…
Classification
- Sector
- Basic Materials
- Industry
- Other Precious Metals & Mining
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 733 SEYMOUR STREET, VANCOUVER, BC
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer